Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Chondrosarcoma | Research article

Differences in clinical characteristics and tumor prognosis between primary and secondary conventional pelvic chondrosarcoma

Authors: Jie Zang, Wei Guo, Rongli Yang, Xiaodong Tang, Haijie Liang

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Chondrosarcoma (CS) most commonly involves the pelvis. This study aimed to analyze differences in clinical characteristics and prognostic factors between primary and secondary conventional pelvic CS, and provide reference for clinical diagnosis and treatment.

Methods

Eighty patients (54 primary cases and 26 secondary cases) with pelvic CS were included in this retrospective study. The tumor site, Enneking stage, soft tissue mass, margin, initial tumor grade, incidence of local recurrence and distant metastasis were evaluated. Kaplan-Meier method was used to calculate the overall survival rate. X2 test and log-rank test were used for univariate analysis, and Cox test was used in multivariate analysis.

Results

The average age of patients with secondary CS was significantly younger than that of patients with primary CS (P < 0.001). The soft tissue mass of patients with secondary CS was significantly larger than that of patients with primary CS (P = 0.002). There was a significant difference in initial tumor pathologic grade between the two groups (P = 0.002). No statistically significant difference was observed in the local recurrence rate between the two groups. The median recurrence time of patients with primary CS after the first treatment was significantly shorter than that of patients with secondary CS (P < 0.001). The overall survival rate of patients with secondary CS was much higher than that of patients with primary CS (P = 0.003). Cox regression analysis showed that the initial tumor grade was an independent factor in the overall survival rate of patients with CS.

Conclusion

There were significant differences in age, soft tissue mass, initial tumor grade, and overall survival rate between the two groups. The overall survival rate of pelvic CS was related to the initial tumor grade of CS.
Literature
5.
go back to reference Benassi MS. Biology of central and peripheral Chondrosarcoma: springer international publishing; 2014.CrossRef Benassi MS. Biology of central and peripheral Chondrosarcoma: springer international publishing; 2014.CrossRef
8.
go back to reference Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am. 2001;83(11):1630–42 Epub 2001/11/10. PubMed PMID: 11701784.CrossRefPubMed Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am. 2001;83(11):1630–42 Epub 2001/11/10. PubMed PMID: 11701784.CrossRefPubMed
11.
go back to reference Ahmed AR, Tan TS, Unni KK, Collins MS, Wenger DE, Sim FH. Secondary Chondrosarcoma in Osteochondroma: report of 107 patients. Clin Orthop Relat Res. 2003;411:193–206.CrossRef Ahmed AR, Tan TS, Unni KK, Collins MS, Wenger DE, Sim FH. Secondary Chondrosarcoma in Osteochondroma: report of 107 patients. Clin Orthop Relat Res. 2003;411:193–206.CrossRef
14.
go back to reference Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer. 1998;82(5):851–9 Epub 1998/03/05. PubMed PMID: 9486573.CrossRefPubMed Kawai A, Healey JH, Boland PJ, Lin PP, Huvos AG, Meyers PA. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer. 1998;82(5):851–9 Epub 1998/03/05. PubMed PMID: 9486573.CrossRefPubMed
16.
go back to reference Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20 Epub 1980/11/01. PubMed PMID: 7449206. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20 Epub 1980/11/01. PubMed PMID: 7449206.
18.
go back to reference Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24 Epub 1986/03/01. PubMed PMID: 3456859. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24 Epub 1986/03/01. PubMed PMID: 3456859.
20.
go back to reference Bus MPA, Campanacci DA, Albergo JI, Leithner A, van de Sande MAJ, Gaston CL, et al. Conventional primary central Chondrosarcoma of the pelvis: prognostic factors and outcome of surgical treatment in 162 patients. J Bone Joint Surg Am. 2018;100(4):316–25. https://doi.org/10.2106/jbjs.17.00105 PubMed PMID: 29462035. Epub 2018/02/21.CrossRefPubMed Bus MPA, Campanacci DA, Albergo JI, Leithner A, van de Sande MAJ, Gaston CL, et al. Conventional primary central Chondrosarcoma of the pelvis: prognostic factors and outcome of surgical treatment in 162 patients. J Bone Joint Surg Am. 2018;100(4):316–25. https://​doi.​org/​10.​2106/​jbjs.​17.​00105 PubMed PMID: 29462035. Epub 2018/02/21.CrossRefPubMed
24.
go back to reference Guo W, Li D, Tang X, Ji T. Surgical treatment of pelvic chondrosarcoma involving periacetabulum. J Surg Oncol. 2010;101(2):160–5.CrossRefPubMed Guo W, Li D, Tang X, Ji T. Surgical treatment of pelvic chondrosarcoma involving periacetabulum. J Surg Oncol. 2010;101(2):160–5.CrossRefPubMed
Metadata
Title
Differences in clinical characteristics and tumor prognosis between primary and secondary conventional pelvic chondrosarcoma
Authors
Jie Zang
Wei Guo
Rongli Yang
Xiaodong Tang
Haijie Liang
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Chondrosarcoma
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07530-9

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine